{
  "symbol": "CDNA",
  "company": "CareDx, Inc.",
  "generated_at": "2026-06-24T07:36:46.190Z",
  "event_count": 3,
  "events": [
    {
      "type": "scout_dossier",
      "ts": "2026-06-18T21:11:53.117Z",
      "summary": "CareDx is a precision medicine company focused on transplant diagnostics (kidney, heart, lung dd-cfDNA; gene expression profiling). The investigation was triggered by 7 Form 4 filings in 14 days — but upon reading each filing, the cluster consists entirely of RSU vesting grants (A-code acquisitions at $0) and pre-scheduled Rule 10b5-1 sales. There are zero open-market discretionary purchases from CEO/CFO or any director. The stock is at a 52-week high ($26.18), has risen ~78% YTD, trades at forward P/E of ~23x with an extreme EV/EBITDA of ~448x given near-zero profitability. Q1 2026 delivered a massive earnings beat (+161% EPS surprise) driven by 39% revenue growth, and the company announced two portfolio-transforming events: acquisition of Naveris (up to $260M oncology MRD) and divestiture of the Lab Products business. Multiple catalysts exist over the next 3-12 months but valuation is stretched for a long-only asymmetric entry.",
      "verdict": "no_anomaly",
      "confidence": 5,
      "tool_calls": 25,
      "walltime_min": 23,
      "debug_path": "dossiers/2026-06-18-CDNA.scout.debug.json"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-16T22:43:49.297Z",
      "skip": true,
      "reason": "Score falls well below the publish threshold due to zero insider buying, bearish options skew, lack of valuation discount, and active anti-signal gates (litigation, reimbursement concentration). With the stock up 58% YTD and insider selling at highs, the risk/reward for any structure is unfavorable.",
      "score": 20,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 10,
        "mispricing": 0,
        "quality": 0,
        "technical": 10
      },
      "debug_path": "drafts/2026-06-16-CDNA.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-16T22:43:10.841Z",
      "summary": "CareDx reported a standout Q1 2026 with +39% YoY revenue growth and EPS of $0.34 vs $0.13 estimate (+162% beat), alongside an announced Naveris oncology acquisition (up to $260M) and lab products divestiture — all positive catalysts for the shares which are up ~58% YTD off a 52-week low. However, the triggering Form 4 cluster is almost entirely routine annual RSU grants to directors at $0 cost basis; there were NO open-market cash purchases by insiders. The sole executive transaction was CEO John Hanna's scheduled sell of ~22K shares (~$528K) via pre-existing 10b5-1 plan — not bullish signaling. Options flow shows a bearish put/call ratio of 3.67:1 and heavy protective positioning, suggesting informed players are hedging rather than betting on continued upside. At forward P/E ~20x with the stock near its 52-week high ($24.85) after a strong run, the risk/reward for an asymmetric long is poor.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 24,
      "walltime_min": 29,
      "debug_path": "dossiers/2026-06-16-CDNA.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "CDNA",
    "call": "BUY",
    "confidence": 5,
    "score": 7,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_up": "+1 (14.2%)",
      "rsi_neutral": "0 (62.6)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (8d ago)",
      "near_52w_high": "+1 (-4.0% from high)"
    },
    "summary": "BUY (score +7) · 12-1 mom 14.2% · RSI 62.6 · above_both · -4.0% from high",
    "last_close": 25.12,
    "one_month_ago_close": 21.57,
    "twelve_month_ago_close": 18.88,
    "twelve_one_momentum_pct": 14.25,
    "rsi_14": 62.6,
    "ma_stack": "above_both",
    "from_period_high_pct": -4.05,
    "period_high": 26.18,
    "price_targets": {
      "bear": 18.33,
      "fair": 24.21,
      "bull": 30.11,
      "bear_return_pct": -27,
      "fair_return_pct": -3.6,
      "bull_return_pct": 19.9,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 21,
        "target_mean": 25.8,
        "target_high": 28,
        "analyst_count": 5
      }
    },
    "generated_at": "2026-06-24T07:36:46.186Z"
  }
}